Sargramostim injection
Products billed under this code include Leukine.
Payment limit per 50 MCG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Leukine.
Payment limit per 50 MCG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Leukine | Partner Therapeutics, Inc | 71837-5843-05 | 25 | $1,561.75 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $62.47 | −$0.004 | 50 MCG | Sargramostim injection | v1, posted September 17, 2026 |
| 3Q26 | $62.474 | +$0.586 | 50 MCG | Sargramostim injection | v1, posted September 15, 2026 |
| 2Q26 | $61.888 | +$0.143 | 50 MCG | Sargramostim injection | v1, posted September 15, 2026 |
| 1Q26 | $61.745 | +$11.38 | 50 MCG | Sargramostim injection | v1, posted September 15, 2026 |
| 4Q25 | $50.365 | −$5.726 | 50 MCG | Sargramostim injection | v1, posted September 8, 2026 |
| 3Q25 | $56.091 | −$3.792 | 50 MCG | Sargramostim injection | v1, posted March 10, 2026 |
| 2Q25 | $59.883 | −$0.135 | 50 MCG | Sargramostim injection | v1, posted March 10, 2026 |
| 1Q25 | $60.018 | −$0.257 | 50 MCG | Sargramostim injection | v1, posted December 19, 2025 |
| 4Q24 | $60.275 | +$0.28 | 50 MCG | Sargramostim injection | v1, posted June 11, 2025 |
| 3Q24 | $59.995 | +$0.54 | 50 MCG | Sargramostim injection | v1, posted June 11, 2025 |
| 2Q24 | $59.455 | +$0.138 | 50 MCG | Sargramostim injection | v1, posted March 11, 2025 |
| 1Q24 | $59.317 | +$1.056 | 50 MCG | Sargramostim injection | v1, posted December 19, 2024 |
| 4Q23 | $58.261 | −$0.05 | 50 MCG | Sargramostim injection | v1, posted October 10, 2024 |
| 3Q23 | $58.311 | +$1.227 | 50 MCG | Sargramostim injection | v1, posted June 5, 2024 |
| 2Q23 | $57.084 | +$0.583 | 50 MCG | Sargramostim injection | v1, posted February 23, 2024 |
| 1Q23 | $56.501 | +$1.058 | 50 MCG | Sargramostim injection | v1, posted December 6, 2023 |
| 4Q22 | $55.443 | +$0.123 | 50 MCG | Sargramostim injection | v1, posted June 22, 2023 |
| 3Q22 | $55.32 | +$1.279 | 50 MCG | Sargramostim injection | v1, posted June 9, 2023 |
| 2Q22 | $54.041 | +$0.483 | 50 MCG | Sargramostim injection | v1, posted December 14, 2022 |
| 1Q22 | $53.558 | +$2.012 | 50 MCG | Sargramostim injection | v1, posted June 8, 2022 |
| 4Q21 | $51.546 | +$2.034 | 50 MCG | Sargramostim injection | v1, posted June 2, 2022 |
| 3Q21 | $49.512 | +$1.101 | 50 MCG | Sargramostim injection | v1, posted June 2, 2022 |
| 2Q21 | $48.411 | +$0.658 | 50 MCG | Sargramostim injection | v1, posted March 1, 2022 |
| 1Q21 | $47.753 | – | 50 MCG | Sargramostim injection | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.